Metabolic Lab · DeCure for X
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for autoimmune polyendocrine syndrome type 1 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for autoimmune polyendocrine syndrome type 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
itchy E3 ubiquitin protein ligase (ITCH) — ITCH is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 3TUG · 2.27 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
Autoimmune polyendocrine syndrome type 1 is a rare autosomal recessive hereditary pathology caused by a defect in the autoimmune regulator gene (AIRE). It develops with endocrine and non-endocrine manifestations in childhood. The disease is characterised by clinical polymorphism, which makes timely diagnosis difficult. One 2024 clinical case describes an 11-year-old patient in whom the course of the disease was erased for a long period. The authors of that case state that a high quality of life for such patients is possible with timely, individually selected substitution therapy, followed by dispensary observation. A separate 2024 paper presents data on the frequency of occurrence, features of the clinical presentation, course, and prognosis, and notes the challenges of diagnosis and therapy choice, and the need for follow-up observation.
No abstract in this set reports any drug trial, any repurposing attempt, or any quantitative outcome such as survival or response rates. The 1999 review describes the syndromes as a rare constellation of autoimmune disorders characterised by more than one endocrine gland failure, with possible hypofunction or hyperfunction of affected organs. The 2019 review identifies new autoantibody targets and provides an up-to-date review of pathophysiological basis, investigations, management and future directions, but gives no concrete numbers.
What is still missing is any clinical trial data, any test of a specific drug, any patient stratification strategy, and any funding for interventional studies. The literature remains limited to case reports and general reviews, with no evidence base for drug repurposing.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractThe polyglandular autoimmune syndromes are a rare constellation of autoimmune disorders characterized by more than one endocrine gland failure occurring in individuals and their families. In addition to endocrine glands, other nonendocrine organs may be targeted by the immune system, resulting in hypofunction as well as hyperfunction of the affected organs.
https://doi.org/10.1007/978-1-59259-704-8_15AbstractIn brief: This article reviews important developments and major advances in characterizing autoimmunity in patients with autoimmune polyendocrine syndromes, such as the identification of new autoantibody targets associated with distinct diseases and their manifestations. The authors also provide an up to date review of pathophysiological basis, investigations, management and future directions for patients with autoimmune polyendocrine syndromes.
https://doi.org/10.1530/ey.16.5.11AbstractAutoimmune polyendocrine syndrome type 1 is a rare autosomal recessive hereditary pathology — a defect in the autoimmune regulator gene (AIRE), which develops with endocrine and non-endocrine manifestations in childhood. The disease is characterized by clinical polymorphism, which makes timely diagnosis difficult. The article describes a clinical case of an 11-year-old patient with autoimmune polyendocrine syndrome type 1, in whom the course of the disease was erased for a long period. The high quality of life of such patients is possible with timely, individually selected substitution therapy, followed by dispensary observation.
https://doi.org/10.21508/1027-4065-2024-69-1-108-113AbstractThe autoimmune polyglandular syndrome is a rare autoimmune disease characterized by simultaneous primary involvement of the endocrine glands and other organs. It is caused by a defect in the AutoImmune REgulator (AIRE) gene. The paper presents data on autoimmune polyglandular syndrome type 1, including the frequency of its occurrence, features of the clinical presentation, course, and prognosis. In the described clinical case, we present patient management with this syndrome, features of the disease course, the challenges of diagnosis and therapy choice, and the need for follow-up observation.
https://doi.org/10.26442/26586630.2024.4.203061Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
